Evidence map›Paper›PMID 41128548›Full record

ArticleJournal of the National Cancer Institute2026

An immunosuppressive tertiary lymphoid structure is associated with adverse prognosis in gastric-type endocervical adenocarcinoma.

Ruiyi Xu, Hong Liu, Tao Zhu, Huarong Tang, Min Wu, Xinyu Yan, Menghan Li, Shuo Yuan, Taotao Yin, Jinglan Chen and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ruiyi XuDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hong LiuDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tao ZhuDepartment of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Huarong TangDepartment of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Min WuDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xinyu YanDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Menghan LiDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shuo YuanDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-7861-5975
Taotao YinDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinglan ChenDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0009-0000-6921-8401
Shuyan WangDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Junbin QianDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0003-1483-1836
Junfen XuDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-2377-0775
Qing ZhangDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, China.ORCID 0009-0001-5829-8327
Bingjian LuZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0001-7309-1116
Hui WangDepartment of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0001-6789-5185

Funding

National Natural Science Foundation of China 82072855National Natural Science Foundation of China 82373260Women's Hospital, School of Medicine, Zhejiang University LY2022004Zhejiang Traditional Chinese Medicine Innovation Team CZ2024009
6 · The paper itself

Abstract

backgroundGastric-type adenocarcinoma (GAC) is the predominant subtype of HPV-independent endocervical adenocarcinoma, characterized by aggressive clinical behavior and poor prognosis. However, its tumor immune microenvironment (TIME) remains largely unexplored.

methodsWe systematically profiled the immune landscape using bulk RNA sequencing and multiplex immunofluorescence staining and comprehensively analyzed the associations between immune features, clinicopathological parameters, and patient outcomes in a multi-institutional cohort of 153 GAC cases.

resultsGAC tumors exhibited sparse T cell but abundant macrophage infiltration, predominantly with M2-polarized macrophages in advanced stage. Tumors with tertiary lymphoid structure (TLS) demonstrated an immunosuppressive milieu characterized by enrichment of B cells, PD1-CD8+ T cells, and regulatory T cells. While TLS-positive patients were associated with poorer prognosis, 2 patients showed improved survival with chemoradiotherapy. Moreover, the TLS and FIGO stage-based prognostic model was robust in the risk stratification for tumor recurrence.

conclusionsWe reveal a distinct immunosuppressive TIME and TLS in GAC. TLS might confer an adverse prognosis. Our findings provide valuable clues for individualized therapy for this aggressive cancer in future.

Indexed as

AdenocarcinomaTertiary Lymphoid StructuresUterine Cervical NeoplasmsAgedFemaleHumansLymphocytes, Tumor-InfiltratingMiddle AgedPrognosisTumor Microenvironment

Identifiers

PMID41128548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.